(NASDAQ: APLS) Apellis Pharmaceuticals's forecast annual revenue growth rate of 44.34% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.22%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.95%.
Apellis Pharmaceuticals's revenue in 2024 is $524,070,000.On average, 8 Wall Street analysts forecast APLS's revenue for 2024 to be $98,377,947,959, with the lowest APLS revenue forecast at $92,953,878,575, and the highest APLS revenue forecast at $116,649,289,533. On average, 7 Wall Street analysts forecast APLS's revenue for 2025 to be $141,801,693,979, with the lowest APLS revenue forecast at $127,797,929,415, and the highest APLS revenue forecast at $166,626,411,426.
In 2026, APLS is forecast to generate $192,513,927,039 in revenue, with the lowest revenue forecast at $172,782,072,376 and the highest revenue forecast at $224,647,642,305.